Craig Fox
Chief Tech/Sci/R&D Officer bij C4X Discovery Ltd.
Profiel
Craig Fox is currently the Director & Chief Scientific Officer at C4X Discovery Ltd.
and an Operating Partner at Oxford Science Enterprises PLC.
Previously, he was the Chief Scientific Officer & Executive Director at C4X Discovery Holdings Plc from 2016 to 2022 and the Director-Respiratory Research at Pulmagen Therapeutics LLP.
He holds a doctorate from the University of Birmingham and an undergraduate degree from the University of Surrey.
Actieve functies van Craig Fox
Bedrijven | Functie | Begin |
---|---|---|
C4X Discovery Ltd.
C4X Discovery Ltd. Pharmaceuticals: MajorHealth Technology C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom. | Chief Tech/Sci/R&D Officer | - |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Private Equity Investor | 01-02-2022 |
Eerdere bekende functies van Craig Fox
Bedrijven | Functie | Einde |
---|---|---|
C4X DISCOVERY HOLDINGS PLC | Chief Tech/Sci/R&D Officer | 31-03-2022 |
Pulmagen Therapeutics LLP
Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Corporate Officer/Principal | 01-01-2010 |
Opleiding van Craig Fox
University of Birmingham | Doctorate Degree |
University of Surrey | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
C4X DISCOVERY HOLDINGS PLC | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
C4X Discovery Ltd.
C4X Discovery Ltd. Pharmaceuticals: MajorHealth Technology C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom. | Health Technology |
Pulmagen Therapeutics LLP
Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Health Technology |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Finance |